Abstract
Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Current Pharmaceutical Biotechnology
Title:Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Volume: 15 Issue: 11
Author(s): Dai Mizuno, Hironari Koyama, Susumu Ohkawara, Yutaka Sadakane and Masahiro Kawahara
Affiliation:
Keywords: Amyloid, combinaconformational disease, calcium homeostasis, synapse.
Abstract: Prion diseases are progressive neurodegenerative diseases that are associated with conformational changes that convert normal cellular prion protein (PrPC) into an abnormal pathogenic prion protein (PrPSc). It is widely recognized that prion diseases are forms of transmissible amyloidosis and are considered to be protein-misfolding diseases (conformational diseases), a category that also includes Alzheimer’s disease. Trace elements play crucial roles in the conformational change affecting PrPC, and increasing evidence suggests that PrPC is a metal-binding protein that is involved in the homeostasis of Cu, Zn, and Fe. In this article, we review the current understanding of links between trace elements and the conformational change to PrPSc, based on our studies using synthetic prion peptides, as well as other new findings. We also focus on PrPSc-induced disruption of Ca homeostasis as a molecular mechanism for neurodegeneration in prion diseases. Possible roles of carnosine (ß-alanyl histidine) as a candidate neuroprotective substance use in prion diseases are also discussed.
Export Options
About this article
Cite this article as:
Mizuno Dai, Koyama Hironari, Ohkawara Susumu, Sadakane Yutaka and Kawahara Masahiro, Involvement of Trace Elements in the Pathogenesis of Prion Diseases, Current Pharmaceutical Biotechnology 2014; 15 (11) . https://dx.doi.org/10.2174/1389201015666141103020625
DOI https://dx.doi.org/10.2174/1389201015666141103020625 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries
Current Radiopharmaceuticals Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
Current Molecular Pharmacology Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery Vitamin E-Related Inhibition of Monocyte 5-Lipoxygenase and Cardiovascular Outcome in Maintenance Hemodialysis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Glycoconjugates in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Multipotent, Permeable Drug ASS234 Inhibits Aβ Aggregation, Possesses Antioxidant Properties and Protects from Aβ-induced Apoptosis In Vitro
Current Alzheimer Research Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimers Disease
Current Alzheimer Research Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology Beneficial Effects of Choline Alphoscerate on Amyloid-β Neurotoxicity in an In vitro Model of Alzheimer’s Disease
Current Alzheimer Research Procathepsin D as a Tumor Marker, Anti-Cancer Drug or Screening Agent
Anti-Cancer Agents in Medicinal Chemistry Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Molecular Imaging of Breast Cancer: Role of RGD Peptides
Mini-Reviews in Medicinal Chemistry GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry